life science Investing News

Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.

life science Investing News

What Does the FDA Think About Psychedelics?

Investing in Pharmaceutical Companies

Psychedelics Celebrates First Business Conference

Due Diligence Critical for Emerging Psychedelics Space

Gwella Mushrooms

Billy Goat Brands

Universal Ibogaine

Psychedelics: Are They the Next Big Thing in Health and Wellness?

Universal Ibogaine CEO Dr. Rami Batal: Well Funded to Develop an Innovative Addiction Treatment Model

Sirona Biochem CEO: Unique Opportunity for Global Success in the Cosmetic and Therapeutic Spaces

5 Top Genetic Testing Stocks

Top NASDAQ Genetics Stocks

Canadian Biotech Company Pursuing Psychedelics with Unique Compound

Love Pharma's Acquisition Will Offer Exclusive Partnership and License with World Renowned University to Conduct Landmark Psilocybin Study

Numinus to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th

Top Canadian Pharma Stocks

Top Canadian Biotech Stocks

Pharmaceutical Industry Overview: Top Regions

Love Pharma

Solarvest BioEnergy

Boosh Plant-Based Brands

Merck Announces First-Quarter 2022 Dividend

IDBS Polar Insight Brings Advanced Data Analytics and Visualization to BioPharma Lifecycle Management

AbbVie Submits Application for Risankizumab in Moderate to Severe Crohn's Disease to European Medicines Agency

COMPASS Pathways to participate in upcoming Evercore, H.C. Wainwright & Berenberg investor conferences

Medtronic receives Health Canada licence for GI Genius intelligent endoscopy module with artificial intelligence system for colonoscopy

Awakn Life Sciences Strengthens Executive Leadership Team

Merck's KEYTRUDA® Approved in Japan in Combination With Chemotherapy for First-Line Treatment of Patients With Radically Unresectable, Advanced or Recurrent Esophageal Carcinoma

FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® as Adjuvant Treatment in BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer and Grants Priority Review

SHAREHOLDER ALERT: CLAIMSFILER REMINDS BMY, OWLT, PTON, ZG INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

Hollister Biosciences Announces Third Quarter Fiscal 2021 Financial Results Including Revenue of USD $14.5M and Adjusted Ebitda of USD $1.2M

Beyond Medical Technologies Ramps Up COVID Mask Manufacturing in Response to New South Africa COVID Variant

MARKETS

COMMODITIES